Skip to main content
. 2023 Jun 5;2023(6):CD011203. doi: 10.1002/14651858.CD011203.pub3

Comparison 1. Alemtuzumab 12 mg versus interferon beta‐1a.

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
1.1 Relapse‐free survival at 24 months 2   Hazard Ratio (IV, Random, 95% CI) 0.50 [0.41, 0.60]
1.1.1 Treatment‐naive 1   Hazard Ratio (IV, Random, 95% CI) 0.45 [0.33, 0.61]
1.1.2 Previously treated 1   Hazard Ratio (IV, Random, 95% CI) 0.53 [0.41, 0.69]
1.2 Relapse‐free survival at 36 months 1 221 Hazard Ratio (IV, Random, 95% CI) 0.31 [0.18, 0.53]
1.3 Sustained disease progression‐free survival at 24 months 2   Hazard Ratio (IV, Random, 95% CI) 0.62 [0.44, 0.87]
1.3.1 Treatment‐naive 1   Hazard Ratio (IV, Random, 95% CI) 0.70 [0.40, 1.22]
1.3.2 Previously treated 1   Hazard Ratio (IV, Random, 95% CI) 0.58 [0.38, 0.89]
1.4 Sustained disease progression‐free survival at 36 months 1 223 Hazard Ratio (IV, Random, 95% CI) 0.25 [0.11, 0.56]
1.5 Adverse events, including serious adverse events at 24 months 2 1248 Risk Ratio (M‐H, Random, 95% CI) 1.04 [1.01, 1.06]
1.5.1 Treatment‐naive 1 581 Risk Ratio (M‐H, Random, 95% CI) 1.04 [1.00, 1.09]
1.5.2 Previously treated 1 667 Risk Ratio (M‐H, Random, 95% CI) 1.03 [1.00, 1.07]
1.6 Adverse events, including serious adverse events at 36 months 1   Risk Ratio (M‐H, Random, 95% CI) Subtotals only
1.7 Change in disability (Expanded Disability Status Scale [EDSS]) at 24 months 2 1199 Mean Difference (IV, Random, 95% CI) ‐0.20 [‐0.60, 0.20]
1.7.1 Treatment‐naive 1 571 Mean Difference (IV, Random, 95% CI) 0.00 [‐0.19, 0.19]
1.7.2 Previously treated 1 628 Mean Difference (IV, Random, 95% CI) ‐0.41 [‐0.62, ‐0.20]
1.8 Change in disability (EDSS) at 36 months 1   Mean Difference (IV, Random, 95% CI) Totals not selected
1.9 New or enlarging T2‐hyperintense lesions at 24 months 2 1238 Risk Ratio (M‐H, Random, 95% CI) 0.74 [0.59, 0.91]
1.9.1 Treatment‐naive 1 581 Risk Ratio (M‐H, Random, 95% CI) 0.82 [0.71, 0.95]
1.9.2 Previously treated 1 657 Risk Ratio (M‐H, Random, 95% CI) 0.66 [0.59, 0.75]
1.10 Dropouts at 24 months 2 1248 Risk Ratio (M‐H, Random, 95% CI) 0.31 [0.22, 0.44]
1.10.1 Treatment‐naive 1 581 Risk Ratio (M‐H, Random, 95% CI) 0.39 [0.24, 0.65]
1.10.2 Previously treated 1 667 Risk Ratio (M‐H, Random, 95% CI) 0.27 [0.19, 0.39]
1.11 Dropouts at 36 months 1   Risk Ratio (M‐H, Random, 95% CI) Subtotals only